Temgoua Mazou Ngou, Kuate Liliane Mfeukeu, Ngatchou William, Sibetcheu Aurelie, Toupendi Zouliatou Nzina, Belobo Grace, Ossa Alice, Kingue Samuel
Faculty of Medicine and Biomedical Sciences, Department of Medicine and Specialities, Yaoundé, Cameroon.
Faculty of Medicine and Pharmaceutical Sciences, Department of Surgery, Douala, Cameroon.
Pan Afr Med J. 2020 Apr 29;35(Suppl 2):11. doi: 10.11604/pamj.2020.35.2.22947. eCollection 2020.
COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.
新冠疫情是一种新出现的心血管危险因素，也是全球死亡的主要原因。血栓栓塞被高度怀疑是这些患者死亡的主要原因，是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的血管炎症导致的。到目前为止，尚无真正治疗新冠病毒病的方法，许多提议的药物正在临床试验中。鉴于新冠病毒病重症患者血栓栓塞事件的高发生率，预防这种病症对于降低这些患者的死亡率至关重要。
